Table 3. Results of the neutralizing antibody, anti-S antibody, and SARS CoV-2 IgG tests.
| Characteristics | GMT (95% CI) | SCR (95% CI) | GMFR (95% CI) | ||
|---|---|---|---|---|---|
| Neutralizing antibody (inhibition) test result | |||||
| At least 2 doses of the vaccine | |||||
| Day 0 | 7.5 (7.3–7.8) | - | - | ||
| Day 35 | 66.1 (65.3–67) | 59.1% (58.0%–60.1%) | 8.6 (8.3–9) | ||
| Day 180 | 39.3 (38–40.6) | 46.2% (44.9%–47.6%) | 4.7 (4.5–4.9) | ||
| Day 194 | 78.4 (76.9–80) | 61.1% (59.3%–62.9%) | 10.1 (9.4–10.8) | ||
| Day 360 | 78.6 (76.8–80.5) | 60.0% (57.7%–62.3%) | 9.9 (9.1–10.7) | ||
| All 3 vaccines | |||||
| Day 0 | 8.5 (8.1–8.9) | - | |||
| Day 35 | 68.9 (67.7–70) | 56.9% (55.4%–58.4%) | 8.1 (7.7–8.5) | ||
| Day 180 | 40.3 (38.9–41.7) | 44.8% (43.3%–46.2%) | 4.5 (4.3–4.8) | ||
| Day 194 | 84.3 (83.3–85.3) | 61.6% (59.7%–63.5%) | 10.6 (9.9–11.4) | ||
| Day 360 | 78.6 (76.8–80.5) | 60.0% (57.7%–62.3%) | 9.9 (9.1–10.7) | ||
| Anti-S antibody (QuantiVac) test result | |||||
| At least 2 doses of the vaccine | |||||
| Day 0 | 15.0 (14.6–15.4) | - | - | ||
| Day 35 | 239.8 (234.3–245.4) | 79.0% (78.1%–79.8%) | 15.6 (15.1–16.1) | ||
| Day 180 | 124.4 (118.3–130.9) | 53.2% (51.8%–54.5%) | 7.8 (7.4–8.2) | ||
| Day 194 | 433.8 (414–454.5) | 77.4% (75.8%–79%) | 27.5 (25.6–29.7) | ||
| Day 360 | 507.9 (477.7–540) | 84.4% (82.6%–86%) | 30.4 (27.8–33.2) | ||
| All 3 vaccines | |||||
| Day 0 | 17.0 (16.3–17.8) | - | - | ||
| Day 35 | 253.3 (245.3–261.5) | 78.4% (77.2%–79.7%) | 14.9 (14.2–15.6) | ||
| Day 180 | 131.2 (124.4–138.3) | 53.0% (51.6%–54.4%) | 7.7 (7.2–8.1) | ||
| Day 194 | 490.3 (470.2–511.3) | 79.1% (77.5%–80.7%) | 29.8 (27.7–32.2) | ||
| Day 360 | 507.9 (477.7–540) | 84.4% (82.6%–86%) | 30.4 (27.8–33.2) | ||
| SARS CoV-2 IgG test result | |||||
| At least 2 doses of the vaccine | |||||
| Day 35 | - | - | - | ||
| Day 180 | 0.6 (0.6–0.7) | - | - | ||
| Day 194 | 2.3 (2.2–2.3) | 34.6% (32.8%–36.5%) | 3.4 (3.2–3.6) | ||
| Day 360 | 2.8 (2.6–3) | 47.3% (44.8%–49.8%) | 4.1 (3.7–4.5) | ||
| All 3 vaccines | |||||
| Day 35 | - | - | - | ||
| Day 180 | 0.7 (0.6–0.7) | - | - | ||
| Day 194 | 2.6 (2.5–2.7) | 37.6% (35.7%–39.6%) | 3.8 (3.6–4.1) | ||
| Day 360 | 2.8 (2.6–3) | 47.3% (44.8%–49.8%) | 4.1 (3.7–4.5) | ||
SARS CoV-2, severe acute respiratory syndrome coronavirus 2; IgG, immunoglobulin G; GMT, geometric mean titer; CI, confidence interval; SCR, seroconversion rate; GMFR, geometric mean fold rise.